Doximity (DOCS) is experiencing a significant downturn, marked by a wave of downgrades from over ten Wall Street firms following the release of its fiscal fourth-quarter results and outlook for fiscal 2027. Shares plummeted approximately 24% on May 14, with a year-to-date decline exceeding 45%. Bank of America (BofA) analyst Allen Lutz reduced the price target from $47 to $38 while maintaining a buy rating, noting a shift in how quickly Doximity can monetize its advancements in clinical AI.
Investors are now faced with the question of whether this reduced outlook accurately reflects the company’s reality or if further declines lie ahead. BofA’s price adjustment is particularly concerning as it signals diminished visibility into growth and heightened risks associated with execution. The company’s fiscal 2027 revenue guidance of $664 to $676 million substantially missed Wall Street’s expectations of approximately $697 million, spurring market apprehension.
Doximity’s challenges are compounded by rising costs related to its AI tools, such as DoxGPT, and increased competition from firms like OpenEvidence. Additionally, management acknowledged a slowdown in demand for digital pharmaceutical advertising, raising broader concerns within the healthcare sector.
For Doximity’s stock to recover, several factors must align, including stability in pharmaceutical advertising budgets, early revenue from AI tools, and consistent market share amidst competition. While the current stock performance suggests a perception of declining business fundamentals, the underlying metrics indicate potential for growth, contingent on how these future developments unfold.
Why this story matters
- Wall Street’s broad downgrade may influence investor sentiment and stock performance.
Key takeaway
- Doximity faces challenges in growth visibility and competitive pressures in the AI space, amid a backdrop of soft pharmaceutical advertising demand.
Opposing viewpoint
- Some analysts believe the company’s fundamentals remain strong and that the long-term prospects of Doximity and its AI initiatives still hold significant potential.
